Region
CDMOs in North America
Compare US and Canadian CDMOs with FDA-registered facilities. Filter by manufacturing type, therapeutic focus, and certifications for domestic drug development and production.
412 companies listed
North American CDMO Manufacturing
North America is the largest pharmaceutical market by revenue and home to hundreds of contract manufacturers. The US alone has over 500 FDA-registered drug manufacturing facilities. For US-based sponsors, domestic CDMOs reduce supply chain risk, simplify regulatory interactions, and shorten shipping timelines for temperature-sensitive biologics.
The BIOSECURE Act is reshaping outsourcing decisions. Companies that previously relied on certain Chinese CDMOs are actively reshoring manufacturing to North American and European partners. This has tightened capacity in biologics and cell therapy manufacturing, making early CDMO engagement more important than ever.
Where are the manufacturing clusters? The Boston-Cambridge corridor leads in biologics and cell therapy. The Research Triangle (NC) has strong small molecule and drug product capacity. San Francisco and San Diego anchor West Coast biologics. Canada offers competitive pricing through federal SR&ED tax credits, with hubs in Montreal and Toronto.
Browse North America CDMOs by country
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Companies (412)
The Ritedose Corporation
United States
The largest US CDMO specializing in sterile Blow-Fill-Seal (BFS) technology for aseptic manufacturing of unit-dose medications. Based in Columbia, South Carolina with a 500,000+ sq ft facility and production capacity of over 2.6 billion units annually. Delivered more than 12 billion doses since 2012 with no patient interruptions. Provides both CDMO services and has a generics division. Offers the largest nebulized drug portfolio in the US. Key products include ophthalmic, respiratory, and inhalation medications. Has co-developed 80%+ of new BFS products over the past decade. 100% customer retention for 25 years. Recent investments include $17M cGMP lab expansion and seventh Syntegon packaging line. 16 FDA-approved products.
Aseptic ProcessingSterile Fill/FinishSterile Injectable
UI Pharmaceuticals
United States
UI Pharmaceuticals (UIP) is the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States, operated by the University of Iowa. They offer comprehensive drug product CDMO services from formulation development through commercialization. In 2023, they launched a new 16,000 sq ft sterile processing facility with fill lines. They serve pharmaceutical, biotech, pediatrics, oncology, and research organizations worldwide.
Frequently Asked Questions
Why choose a North American CDMO?+
Proximity to the FDA simplifies regulatory interactions and inspections. Shorter supply chains reduce risk for temperature-sensitive products. Time zone alignment improves project communication. For US-market products, domestic manufacturing avoids import complexities and potential trade disruptions. The BIOSECURE Act may also require US government-funded programs to use non-restricted CDMOs.
How does the BIOSECURE Act affect CDMO selection?+
The BIOSECURE Act restricts US government agencies from contracting with companies that use certain foreign biotechnology companies of concern for manufacturing. While primarily targeting government-funded work, it signals broader supply chain decoupling. Pharma and biotech companies are proactively shifting manufacturing to North American and European CDMOs to avoid future restrictions and supply disruptions.
Related Categories
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
